All In Biotech

Drug Trial Radar · NCT04054414

PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury

A Prospective, Multicentric, Randomized, Double Blind, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Patients of Acute Spinal Cord Injury

Last checked: Nov 19, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 10, 2019

Primary completion

Jun 2026

Study completion Jul 2026

Sponsor

Lead sponsor
Pharmazz, Inc.Industry
Sponsor type
Industry
First posted
Aug 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in patients of acute spinal cord injury.

Conditions

  • Acute Spinal Cord Injury

Interventions

  • Normal Saline along with standard treatmentDrug

    The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.

  • PMZ-1620 along with standard treatmentDrug

    PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of PMZ-1620 related adverse eventsTime frame: 90 days
  2. Number of patients not receiving full treatmentTime frame: 90 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre

    Belagavi, India · Not yet recruiting

  • Institute of Postgraduate Medical Education & Research and SSKM Hospital

    Kolkata, India · Recruiting

  • King George's Medical University

    Lucknow, India · Recruiting

  • Rahate Surgical Hospital & ICU

    Nagpur, India · Recruiting

  • Indian Spinal Injury Centre

    New Delhi, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.